Publication Name	World Journal of Gastroenterology
Manuscript ID	3865
Country	Greece

Received	2013-05-29 08:42
Peer-Review Started	2013-05-29 10:53
First Decision by Editorial Office Director
Return for Revision	2013-07-04 14:08
Revised	2013-07-07 04:00
Publication Fee Transferred
Second Decision by Editor	2013-07-19 11:25
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-07-19 11:45
Articles in Press
Edit the Manuscript by Language Editor	2013-07-23 23:21
Typeset the Manuscript	2013-08-06 10:11
Publish the Manuscript Online	2013-08-19 18:22

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Manuscript Source	Invited Manuscript
All Author List	Efstathios T Pavlidis and Theodoros E Pavlidis
Funding Agency and Grant Number
Corresponding Author	Theodoros E Pavlidis, MD, PhD, Professor, Second Surgical Propedeutic Department, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Konstantinoupoleos 49, 54642 Thessaloniki, Greece. pavlidth@med.auth.gr
Key Words	Angiogenesis; Vascular endothelial growth factor; Anti-angiogenic agents; Bevacizumab; Avastin; Cancer targeted therapy; Colorectal cancer
Core Tip	Modern targeted therapy with anti-angiogenic agents is based on inhibition of angiogenesis, as the formation of new vessels is crucial for the growth and metastasis of malignant cells. Recent studies on the biological agent, bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor activity, have shown improved outcome in advanced colorectal cancer. The combination of irinotecan, capecitabine and bevacizumab is currently the most frequently used regime in the treatment of metastatic colorectal cancer with improved response rates. However, the rare side-effects of bevacizumab should always be considered.
Publish Date	2013-08-19 18:22
Citation	Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World J Gastroenterol 2013; 19(31): 5051-5060
URL	http://www.wjgnet.com/1007-9327/full/v19/i31/5051.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i31.5051

Full Article (PDF)	WJG-19-5051.pdf
Manuscript File	3865-Review.doc
Answering Reviewers	3865-Answering reviewers.pdf
Copyright License Agreement	3865-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	BV in malignancy WJG.doc
Non-Native Speakers of English Editing Certificate	3865-Language certificate.pdf
Peer-review Report	3865-Peer reviews.pdf
Scientific Editor Work List	3865-Scientific editor work list.doc